Abstract:

In the article considers modern commercial method of production is demanded used in oncology medical product radiopharmaceutical ¹⁸F-fluorodeoxyglucose (2-fluoro,¹⁸F-2-deoxy-D-glucose, ¹⁸F-FDG), are presented the process steps and operation of synthesis, quality control procedures, briefly described the requirements for packaging and labeling of radiopharmaceutical.

References

1.     Kam Leung. [¹⁸F]Fluoro-2-deoxy-2-D-glucose in Molecular Imaging and Contrast Agent Database (MICAD). National Center for Biotechnology Information, NLM, NIH, Bethesda, MD. 2005.

2.     Min-Fu Yang, Diwakar Jain, Zuo-Xiang He. ¹⁸F-FDG Cardiac Studies for Identifying Ischemic Memory. Curr Cardiovasc Imaging Rep. 2012; Dec, 5:383-389.

3.     Ghesani M., Depuey E. G., Rozanski A. Role of F-¹⁸ FDG positron emission tomography (PET) in the assessment of myocardial viability. Echocardiography. 2005 Feb; 22(2): 165-77.

4.     Nose H., Otsuka H., Otomi Y et al. Evaluation of normal physiologic left ventricular myocardial ¹⁸F-FDG uptake at fasting state. European Congress of Radiology. 2012. Vienna, Austria. URL: http://posterng.netkey.at/esr/ viewing/index.php?module=viewing_poster&doi=10.1594 /ecr2012/C-1192 2012.

5.     Dong Soo Lee, Sang Kun Lee, Myung Chul Lee. Functional Neuroimaging in Epilepsy: FDG PET and Ictal SPECT. Korean Med Sci. 2001;16: 689-96.

6.     Teune L. K., Bartels A. L., Leenders K. L. FDG-PET Imaging in Neurodegenerative Brain Diseases // Functional Brain Mapping and the Endeavor to Understand the Working Brain edited by Francesco Signorelli and Domenico Chirchiglia, 2013.

7.     Sanchez-Catasis C. A., Vallez, Garcha D., Le Riverend Morales E., Galvizu Sбnchez R. Traumatic Brain Injury: Nuclear Medicine Neuroimaging .PET and SPECT in Neurology. 2014; 923-946.

8.     Masangkay N., Basu S., Moghbel M. et al. Brain ¹⁸F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings. Nucl Med Commun. 2014 Oct; 35 (10): 1038-46.

9.       Statistika zlokachestvennyh novoobrazovanij v Rossii i stranah SNG v 2012 g. Pod redakciej M.I. Davydova, E.M. Aksel'. [Statistics of malignant neoplasms in Russia and CIS countries in 2012. Edited by M.I. Davydova, E.M. Axel.] Moskva, 2014. - 226 s [In Russ].

10.   Jones S. C., Alavi A., Christman D. et al. The radiation dosimetry of 2 [F-¹⁸]fluoro-2-deoxy-D-glucose in man. J Nucl Med. 1982; 23, 613-617.

11.   Kuwabara H., Gjedde A. Measurements of glucose phosphorylation with FDG and PET are not reduced by dephosphorylation of FDG-6-phosphate. J Nucl Med. 1991 Apr; 32(4): 692-8.

12.   Data are from International Commission on Radiological Protection. Radiation Dose to Patients from Radiopharmaceuticals. St. Louis, MO. Elsevier; 2000:49. ICRP publication 80.

13.   Ido T., Wan C. N., Fowler J. S. Fluorination with F2: convenient synthesis of 2-deoxy-2-fluoro-d-glucose. J Org Chem. 1977; 42: 2341-2.

14.   Hamacher K., Coenen H. H., Stacklin G. Efficient stereospecific synthesis of no-carrier-added 2-[¹⁸F]- fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986; 27: 235-8.

15.   Toorongian S. A., Mulholland G. K., Jewett D. M. et al. Routine production of 2-deoxy-2-[¹⁸F]fluoro-D- glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Int J Rad Appl Instrum B. 1990; 17 (3): 273-9.

16     Normy radiacionnoj bezopasnosti (NRB-99/2009). [Norms of radiation safety (NRB-99/2009).] SP 2.6.1.2523-09.[In Russ].

17.   Osnovnye sanitarnye pravila obespecheniya radiacionnoj bezopasnosti (OSPORB-99/2010). [Basic sanitary rules for ensuring radiation safety (0SP0RB-99/2010)]. SP 2.6.12612-10 [In Russ].

18.   SanPiN 2.6.1.3288-15 «Gigienicheskie trebovaniya po obespecheniyu radiacionnoj bezopasnosti pri podgotovke i provedenii pozitronnoj ehmissionnoj tomografii». [Hygienic requirements for ensuring radiation safety in the preparation and conduct of positron emission tomography.] [ In Russ].

19.   N.A. Gomzina, D.A. Vasil’ev, R.N. Krasikova. Optimization of Automated Synthesis of 2-[¹⁸F]Fluoro- 2-deoxy-D-glucose Involving Base Hydrolysis. Radiochemistry. 2002; 44 (4): 403-409.

20.   Gopal B. Saha. Basics of PET Imaging: Physics, Chemistry and Regulations. - 3th ed. - New York: Springer International Publishing, 2016; 165.

Abstract:

Aim: was to estimate the diagnostic value of PET with ¹⁸F-Choline and ¹⁸F-FDG in case of mixed hepatocellular (HCC) and cholangiocellular cancer (CCC).

Materials and methods: PET/CT with ¹⁸F-Choline and ¹⁸F-FDG was performed on 70 years old patient, with diagnosed hepatobilliary cancer. CT scan and MRI with intravenous contrast-enhanced, histological and immunohistochemical study of postoperative material (right-sided hemihepatectomy) were also performed.

Results: difference in the accumulation of ¹⁸F-Choline and ¹⁸F-FDG in some areas of mixed hepatocellular and cholangiocellular cancer was detected: in the field of cholangiocellular cancer and ir the field of poorly differentiated hepatocellular cancer.

Conclusions: ¹⁸F-choline has a low diagnostic value in the detection of cholangiocellular cancer and poorly differentiated HCC, in contrast to ¹⁸F-FDG, whereas at high differentiated HCC study, ¹⁸F-choline is more preferable. Diagnostic value of ¹⁸F-FDG at high differentiated HCC is extremely low.

References

1.     Patjutko Ju.I., Sagajdak I.V., Chuchuev E.S. Gepatocelljuljarnyj rak pecheni [Hepatocellular cancer]. Bjulleten' medicinskih internet-konferencij. 2011;1: 35-61 [In Russ].

2.     Chissov V.I. Onkologija [Oncology]. M.: Gjeotar-Media. 2007; 391-399 [In Russ].

3.     Sukonko O.G. Gepatocelljuljarnyj rak. Algoritm diagnostiki i lechenija zlokachestvennyh novoobrazovanij[Hepatocellular cancer. Algorithm of diagnostics and treatment of malignant neoplasms] M.: Media Sfera. 2012; 127-135 [In Russ] .

4.     Bosh F.X., Ribes J., Borras J. Epidemiology of primary liver cancer. Semin. Liverdis., vol.19. 1999; 271-285.

5.     Beasley R.P., Hwang L.Y Overview on the epidemiology of hepatocellular carcinoma. Viral hepatitis and liver disease. 1991; 532-535.

6.     Huo T.I., Lee S.D., Wu J.C. For hepatocellular carcinoma: look for a perfect classification system. J. Hepatol. 20-4; .40(6): 1041-1042.

7.     Barazani Y, Hiatt J.R., Tong M.J. et al. dironic viral hepatitis and hepatocellular carcinoma. World J. Surg. 2007; 31: 1245-250.

8.     Jeong S., Aviata H., Katamura Y Low-dose intermittent interferon - alpha-therapy for HCV - related liver cirrosis after curative treatment of hepatocellular carcinoma. World J. Gastroenterology. 2007;113; 5188-5195.

9.     Zogot S.R., Akberov R.F. Gepatocelljuljarnyj rak (jepidemiologija, luchevaja diagnostika, sovremennye aspekty lechenija). Lekcii dlja vrachej obshhej praktiki, onkologija, prakticheskaja medicina, hirurgija [Hepatocellular cancer (epidemiology, radiodiagnostics, modern aspects of treatment). Lectures for general practice doctors, oncology, practical medicine, surgery]. 2013; 112-115 [In Russ].

10.   Majstrenko N.A., Shejko S.B., Alent'ev A.V. Holangiocelljuljarnyj rak (osobennosti diagnostiki i lechenija) [Cholangiocellular cancer (features of diagnostics and treatment)]. Prakticheskaja onkologija. 2009; 9(4): 229-236 [In Russ].

11.   Ward J., Robinson P. How to detect hepatocellular carcinoma in cirrhosis. Eur. Radiology. 2002; 2258-2273.

12.   Zhang F., Chen X.-P., Zhang W. et al. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology. 2008; 52: 224-232.

13.   Caturelli E., Pompili M. Hemangioma-like lesions in chronic liver disease: diagnostic evaluation in patients. Radiology. 2001; 337-342.

14.   Matsui O., Kadoya M., Kameyama T. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology. 1991; 493-497.

15.   Xu H.X., Liu G.J., Lu M.D. Characterization of focal liver lesions using contrast-enhanced sonography with a low mechanical index mode and a sulfur hexafluoride-filled microbubble contrast agent. J. Clin Ultrasound. 2006; 261-272.

16.   Lencioni R., Piscaglia F. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. Journal Of Hepatology. 2008; 48: 848-857.

17.   Prokop M. Spiral and multislice computed tomography of the body. Georg Thieme Verlag. 2003; Р 234-240.

18.   Tiferes D., D’ippolito G. Liver neoplasms: imaging characterization. Radiol. Bras. 2008; 41(2): 119-127.

19.   Medvedeva B.M., Lukjanchenko A.B. Vozmozhnosti MRT v diagnostike gepatocelljuljarnogo raka u pacientov s cirrozom pecheni [Possibilities of MRI in diagnostics of hepatocellular cancer in patients with liver cirrhosis ]. Rejr. 2013; 3(2): 63 [In Russ].

20.   Jeong Y, Yim N., Kang H. Hepatocellular carcinoma in the cirrhotic liver with helical CT and MRI: imaging spectrum and pitfalls of cirrhosis-related nodules. Ajr. 2005; 1024-1032.

21.   Lee M.H., Kim S.H., Park M.J., Park C.K. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. Ajr. 2011; 197: 868-875.

22.   Nasu K., Kuroki Y, Tsukamoto T. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. Ajr. 2009; 193: 438-444.

23.   Ferucci J. MRI of the liver. Amer. J. Roentgenol. 1985;147: 1103-1116.

24.   Yamamoto Y, Nishiyama Y Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. The journal of nuclear medicine. 2008; 49(8): 1245-1248.

25.   Hwang K.H., Choi D.-J. Evaluation of patients with hepatocellular carcinomas using [11C]-acetate and [18F]-FDG PET/CT: a preliminary study. Radiation and isotopes. 2009; 67: 1195-1198.

26.   Talbot J., Gutman F. PET/CT in patients with hepatocellular carcinoma using [18F]- fluorocholine: preliminary comparison with [18F]-FDG PET/CT. Eur. J. Nucl. Med. 2006; 33: 1285-1289.

27.   Chang M., Seungmin B. Usefulness of 18F-fluo- rodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. Journal of gastroenterology and hepatology. 2008; 23: 759-765.

28.   Kluge R., Schmidt F., Caca K. Positron emission tomography with [18F]fluoro-2-deoxy-d-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001; 33:1029-1035.

29.   Kuang Y, Salem N. Transport and metabolism of radiolabeled choline in hepatocellular carcinoma. Molecularрharmaceutics. 2010; 6: 2077-2092.

30.   Trojan J., Schroeder O., Raedle J. Fluorine-18FDG positron emission tomography for imaging of hepatocellular carcinoma. Am. J. Gastroenterol. 1999; 94: 3314-3319.

31.   Esschert J.W., Bieze M. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18F-fluorocholine PET/CT. Eur. J. Nucl. Med. 2011; 38: 436-440.

32.   Lee J., Paeng J. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J. Nucl. Med. 2009; 50: 682-687.

33.   Kuang Y, Salem N. Imaging lipid synthesis in hepatocellular carcinoma with [methyl-11C]-choline: correlation with in vivo metabolic studies. J. Nucl. Med. 2011; 52: 98-106.

34.   Bosman F., Carneiro F., Ruban R. Classification of tumors of the digestive system. 2010; 201-207.